Gregory K. Reid

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Guillermo Garcia‐Manero, Sarit Assouline, Jörge E. Cortes et al. · Blood · 2008 · 234 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

Eric Winquist, Jennifer J. Knox, Jean-Pierre M. Ayoub et al. · Investigational New Drugs · 2006 · 131 citations

Medicine, Oncology, Pharmacology +15

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Lillian L. Siu, Ignacio Durán, Wells A. Messersmith et al. · Journal of Clinical Oncology · 2008 · 118 citations

Medicine, Oncology, Pharmacology +16

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Ruth Plummer, Laura Vidal, Mark Lesley et al. · Clinical Cancer Research · 2009 · 111 citations · Full text

Medicine, Oncology, Pharmacology +14

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

Claire Bonfils, Ann Kalita, Marja Dubay et al. · Clinical Cancer Research · 2008 · 100 citations · Full text

Medicine, Oncology, Pharmacology +14